NovaBay Pharmaceuticals Inc at SRAX Sequire Biotechnology Conference (Virtual) Transcript
Thank you for joining us today. I am Justin Hall, CEO of NovaBay Pharmaceuticals, and we're going to talk today a little bit about our company, our three verticals and the investment opportunity. We are traded on the NYSE American under the symbol NBY.
Our forward-looking statements, so everything that I say to date is current only as of today's date, and we will, of course, put out public statements as things develop and update the public sector.
So starting out with just a general overview of what NovaBay Pharmaceuticals is. We are a commercial pharmaceutical company with three different verticals. The first vertical is Avenova for eyecare. The second one is DERMAdoctor for skin care. And then the third one is NeutroPhase, PhaseOne for the wound care market.
So our core product and what brings in most of the revenue is Avenova in the eye care market. So we'll go through that first. And the second is a fairly recent acquisition. We acquired a company by the name of DERMAdoctor in November 2021, and that brought another vertical
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
